Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (NASDAQ: VERA) announced inducement awards granted to eleven new employees on May 5, 2025. The awards include non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares. The stock options have an exercise price of $25.53 per share, based on VERA's closing price on May 5.
The stock options will vest over 4 years, with 25% vesting on the first anniversary and the remainder vesting monthly over 36 months. The RSUs will vest over 4 years, with 25% vesting annually starting May 20, 2025. Both awards are contingent on continued employment with Vera.
Vera Therapeutics (NASDAQ: VERA) ha annunciato il 5 maggio 2025 l'assegnazione di premi di incentivo a undici nuovi dipendenti. I premi comprendono opzioni su azioni non qualificate per l'acquisto di 111.750 azioni di azioni ordinarie di Classe A e unità di azioni vincolate (RSU) per 62.575 azioni. Il prezzo di esercizio delle opzioni è di 25,53 $ per azione, basato sul prezzo di chiusura di VERA del 5 maggio.
Le opzioni azionarie matureranno in 4 anni, con il 25% che matura al primo anniversario e il resto che matura mensilmente nei successivi 36 mesi. Le RSU matureranno in 4 anni, con il 25% che matura annualmente a partire dal 20 maggio 2025. Entrambi i premi dipendono dalla continuazione del rapporto di lavoro con Vera.
Vera Therapeutics (NASDAQ: VERA) anunció el 5 de mayo de 2025 la concesión de premios de incentivo a once nuevos empleados. Los premios incluyen opciones sobre acciones no calificadas para comprar 111,750 acciones de acciones comunes Clase A y unidades de acciones restringidas (RSU) por 62,575 acciones. El precio de ejercicio de las opciones es de $25.53 por acción, basado en el precio de cierre de VERA el 5 de mayo.
Las opciones sobre acciones se consolidarán en 4 años, con un 25% consolidado en el primer aniversario y el resto consolidándose mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en 4 años, con un 25% consolidado anualmente a partir del 20 de mayo de 2025. Ambos premios dependen de la continuidad del empleo con Vera.
Vera Therapeutics (NASDAQ: VERA)는 2025년 5월 5일에 11명의 신입 직원에게 인센티브 상을 부여했다고 발표했습니다. 이 상에는 111,750주의 클래스 A 보통주를 매수할 수 있는 비공인 스톡옵션과 62,575주의 제한 주식 단위(RSU)가 포함됩니다. 스톡옵션의 행사가격은 5월 5일 VERA 종가 기준 $25.53입니다.
스톡옵션은 4년에 걸쳐 권리가 취득되며, 1주년에는 25%가 취득되고 나머지는 36개월 동안 매월 취득됩니다. RSU는 4년에 걸쳐 권리가 취득되며, 2025년 5월 20일부터 매년 25%씩 취득됩니다. 두 상 모두 Vera와의 지속적인 근무가 조건입니다.
Vera Therapeutics (NASDAQ : VERA) a annoncé le 5 mai 2025 l'attribution de primes d'incitation à onze nouveaux employés. Les primes comprennent des options d'achat d'actions non qualifiées pour 111 750 actions ordinaires de classe A et des unités d'actions restreintes (RSU) pour 62 575 actions. Le prix d'exercice des options est de 25,53 $ par action, basé sur le cours de clôture de VERA le 5 mai.
Les options d'achat d'actions seront acquises sur 4 ans, avec 25 % acquis au premier anniversaire et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises sur 4 ans, avec 25 % acquis annuellement à partir du 20 mai 2025. Les deux primes sont conditionnées à la poursuite de l'emploi chez Vera.
Vera Therapeutics (NASDAQ: VERA) gab am 5. Mai 2025 die Gewährung von Anreizprämien an elf neue Mitarbeiter bekannt. Die Prämien umfassen nicht qualifizierte Aktienoptionen zum Kauf von 111.750 Aktien der Klasse A Stammaktien und Restricted Stock Units (RSUs) für 62.575 Aktien. Der Ausübungspreis der Aktienoptionen beträgt 25,53 $ pro Aktie, basierend auf dem Schlusskurs von VERA am 5. Mai.
Die Aktienoptionen werden über 4 Jahre vesten, wobei 25 % am ersten Jahrestag und der Rest monatlich über 36 Monate vesten. Die RSUs vesten über 4 Jahre, mit 25 % jährlich beginnend am 20. Mai 2025. Beide Prämien setzen eine fortgesetzte Beschäftigung bei Vera voraus.
- None.
- None.
BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on May 5, 2025 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
What type of inducement awards did Vera Therapeutics (VERA) grant to new employees in May 2025?
What is the exercise price for VERA's stock options granted on May 5, 2025?
What is the vesting schedule for Vera Therapeutics' stock options granted in May 2025?
How do the RSUs vest in Vera Therapeutics' May 2025 inducement grants?
